Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Victory Capital Management Inc.

Key Points

• Victory Capital Management Inc. decreased its holdings in Nurix Therapeutics by 50.7% in the first quarter, owning 29,660 shares after selling over 30,000 shares.
• Nurix Therapeutics reported an earnings per share (EPS) of ($0.52) for the last quarter, surpassing analysts' expectations of ($0.79).
• The stock has experienced a 2.0% decrease recently, opening at $11.04, with a 52-week range of $8.18 to $29.56.

Victory Capital Management Inc. reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 50.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,660 shares of the company's stock after selling 30,552 shares during the period. Victory Capital Management Inc.'s holdings in Nurix Therapeutics were worth $352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in NRIX. GF Fund Management CO. LTD. acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at $28,000. Aquatic Capital Management LLC acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at $87,000. Exchange Traded Concepts LLC lifted its stake in shares of Nurix Therapeutics by 38.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after purchasing an additional 2,562 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at $164,000.

Nurix Therapeutics Stock Down 2.0%

Nurix Therapeutics stock opened at $11.04 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $29.56. The firm has a market capitalization of $844.01 million, a price-to-earnings ratio of -4.23 and a beta of 2.14. The company has a fifty day simple moving average of $11.82 and a 200-day simple moving average of $13.03.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The firm had revenue of $44,056 billion during the quarter, compared to analyst estimates of $16.26 million. On average, research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 4,308 shares of the company's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the completion of the sale, the insider owned 69,023 shares of the company's stock, valued at approximately $828,966.23. This represents a 5.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 5,402 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $11.03, for a total transaction of $59,584.06. Following the completion of the sale, the chief financial officer directly owned 35,512 shares of the company's stock, valued at $391,697.36. This represents a 13.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,014 shares of company stock valued at $163,014 in the last three months. 7.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on NRIX shares. Stephens restated an "overweight" rating and set a $30.00 price objective on shares of Nurix Therapeutics in a research report on Thursday, July 10th. Stifel Nicolaus reduced their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating for the company in a research report on Wednesday, April 9th. HC Wainwright reduced their price objective on shares of Nurix Therapeutics from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, July 14th. Wells Fargo & Company reduced their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Finally, Needham & Company LLC restated a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $28.87.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.